We’ve been waiting for the $100 genome for a long time and now it’s here. Check out what our consultants had to say about this big news and other landmark announcements at AGBT 2020.

There’s so much more to the UK biotech scene than just London and Cambridge. In the North, we're surrounded by many fascinating companies who’re innovating and conducting crucial research.

It's humbling to see how the life science community has come together to combat the coronavirus. Here's what's happening in diagnostics.

Innovative and pioneering, Synthego, a provider of synthetic RNA solutions for CRISPR Genome Engineering, are looking to grow their team.

Reported to correct 89% of pathogenic human gene variants, prime gene editing has the potential to target over 75,000 different mutations in treatment. 

Our specialist in lab equipment and technology, Lucy Smith, is looking to get in touch with senior leaders in the life science space to learn more about connectivity.

I’ve lost count of the times I’ve seen ‘PhD preferred’, while recruiting for positions in R&D and product development. In the modern life science talent market, are PhDs really so important?

Our Principal Consultant, Adam Butler, talks about the miracles of Stem Cell therapy, the issues surrounding it and the most high-profile case in the treatments' existence.

In an industry as fast paced as the specialty chemicals sector, it's almost impossible to predict the future, but we wanted to try.

Identifying the next big trend in a market like specialty chemicals can be gold dust for any company or individual savvy enough to see it.

In today's hyper-connected world, what's the point of conferences? Our Associate Director Jack Shute asked experts from across the speciality chemical space and some of his CM Life Science colleagues to find out.

Lessons in lateral flow don't come much better than from a founding father of the technology. That's just what we got by speaking with Paul Davis, Co-founder and Chief Scientific Officer at Mologic.